Christine Chung, MD
Medical Oncology · Tampa, FLNPI 1881778983
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $49,781 of the $61,921 with a category attached, or 80.4%. 14 manufacturers reported payments, led by Genmab U.S., Inc. at 37.1% of the total. Reporting peaked in 2023 at $36,966 and has fallen 83.1% since, to $6,249 in 2025.
Across 43 payments — averaging $1440.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genmab U.S., Inc.$23K
- AVEO Pharmaceuticals, Inc.$10K
- Regeneron$7K
- Exelixis Inc.$5K
- E.r. Squibb & Sons, L.L.C.$4K
- Seagen Inc.$4K
- plus $9K from 8 others
Across 247 payments — averaging $26,460 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$3.4M
- Lilly USA, LLC$1M
- Regeneron$603K
- E.r. Squibb & Sons, L.L.C.$477K
- AVEO Pharmaceuticals, Inc.$307K
- Pfizer$271K
- plus $502K from 5 others
What the payments were for
- Consulting fees$49,78180%
- Speaking & faculty fees$9,19715%
- Travel & lodging$1,4462%
- Food & beverage$1,4442%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genmab U.S., Inc. | 4 | $23,002 |
| AVEO Pharmaceuticals, Inc. | 7 | $10,307 |
| Regeneron | 7 | $6,791 |
| Exelixis Inc. | 4 | $4,782 |
| E.r. Squibb & Sons, L.L.C. | 6 | $4,092 |
| Seagen Inc. | 3 | $4,073 |
| Pfizer | 2 | $3,980 |
| Merck | 1 | $1,500 |
| Janssen Research & Development, LLC | 1 | $1,410 |
| Histosonics, Inc. | 2 | $1,122 |
| F. Hoffmann-la Roche AG | 2 | $597 |
| Eisai Inc. | 2 | $190 |
| EMD Serono, Inc. | 1 | $53 |
| Puma Biotechnology, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$61,921 in reported general payments places this provider in the 85th percentile of 507 medical oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RetevmoSelpercatinib | 11 | $42,001 |
| Oxycodone Hcl | 38 | $2,731 |
| Levothyroxine Sodium | 29 | $246 |
| Gabapentin | 11 | $164 |
| Lorazepam | 17 | $109 |
| Prednisone | 18 | $59 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Tampa
- Eduardo SotomayorTampa$362K
- Kenneth ShainTampa$341K
- Ivan BorrelloTampa$336K
- Alberto ChiapporiTampa$325K
- Jingsong ZhangTampa$220K
- Sameh GaballaTampa$214K
- Adil DaudTampa$204K
- Jeffrey WeberTampa$193K
- Mayer FishmanTampa$193K
- Jonathan StrosbergTampa$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.